OMOLOLA OTUBAGA: Open Payments
NPI 1033595566 · FAYETTEVILLE, GA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$822 in 42 payments from 11 companies in 2025. Trend: 2023 $706 · 2024 $599 · 2025 $822
Food & beverage: $822
| Company | Payments | Amount |
|---|---|---|
| ABBVIE INC. | 13 | $174 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 3 | $145 |
| Indivior Inc. | 7 | $144 |
| Supernus Pharmaceuticals, Inc. | 7 | $113 |
| Otsuka America Pharmaceutical, Inc. | 3 | $57 |
| Janssen Pharmaceuticals, Inc | 2 | $49 |
| Alkermes, Inc. | 2 | $43 |
| Bausch Health US, LLC | 2 | $39 |
| Axsome Therapeutics, Inc. | 1 | $20 |
| Teva Pharmaceuticals USA, Inc. | 1 | $20 |
Products named: VRAYLAR, CAPLYTA, SUBLOCADE, Qelbree, REXULTI, ARISTADA, APLENZIN, SPRAVATO.
Industry payments across GA — which companies pay providers there.
